BMRN Biomarin Pharmaceutical (BMRN) Insider Trading, Ownership & Congress Trades
Pharma & Biotech · Pharmaceutical preparations · CIK 0001048477
Form 144 · 1
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
292
13F, latest reported quarter
What the filings say about BMRN
Insiders, 180 days
-$1.3M net sold
2 sellers · 0% of sales under a 10b5-1 plan
Planned sales (Form 144), 90 days
$1.2M
1 notice
Biomarin Pharmaceutical insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
Over the last 180 days, BIOMARIN PHARMACEUTICAL INC insiders sold a net $1.3M of stock across 120 Form 4 purchases and sales, with no insider buying. Source: SEC Form 4 filings, as of 2026-10-28.
Insider
Filed
Shares
Value
Since filing
Context
- 13 earlier Form 4 trades (code P or S) here by this insider (13 sales), the last on Feb 26, 2026.
- The trade is 28.8% of the 61,003 shares held after it.
- No other insider sold within 30 days.
- 292 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: EVP, Chief Legal Officer Davis George Eric sold about $1.2M of BMRN on Sep 2, 2026; 292 funds added in the latest 13F quarter.Context
- 1 earlier Form 4 trade (code P or S) here by this insider (1 sale), the last on Feb 26, 2026.
- The trade is 6.3% of the 51,818 shares held after it.
- No other insider sold within 30 days.
- 292 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: EVP, Chief R&D Officer Friberg Gregory R sold about $176.7K of BMRN on May 7, 2026; 292 funds added in the latest 13F quarter.Context
- 4 earlier Form 4 trades (code P or S) here by this insider (4 sales), the last on Mar 6, 2025.
- The trade is 20.6% of the 79,953 shares held after it.
- 2 other insiders sold within 30 days.
- 292 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: EVP, Chief Technical Officer Guyer Charles Greg sold about $996.7K of BMRN on Mar 11, 2026; 2 other insiders sold within 30 days and 292 funds added in the latest 13F quarter.Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 16.8% of the 37,578 shares held after it.
- 2 other insiders sold within 30 days.
- 292 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: EVP, Chief R&D Officer Friberg Gregory R sold about $382.0K of BMRN on Feb 26, 2026; 2 other insiders sold within 30 days and 292 funds added in the latest 13F quarter.Context
- 12 earlier Form 4 trades (code P or S) here by this insider (12 sales), the last on May 28, 2024.
- The trade is 36.0% of the 72,453 shares held after it.
- 2 other insiders sold within 30 days.
- 292 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: EVP, Chief Legal Officer Davis George Eric sold about $1.6M of BMRN on Feb 26, 2026, the largest insider sale at the company since 2024; 2 other insiders sold within 30 days and 292 funds added in the latest 13F quarter.120 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
net -$1.3M over 180 days
-$1.2M over 90 days
below 65% of Pharma & Biotech
Congress
no House purchase disclosed in the last 12 months
Funds
292 funds bought in last quarter
more than 95% of Pharma & Biotech
Revenue
+12.9% year over year
more than 62% of Pharma & Biotech
Margin
10.8% net margin
more than 82% of Pharma & Biotech
Buybacks
no share repurchases reported
Short interest
6.0% of the float short (float per yahoo 2026-10-26) · 5.5 days to cover · settled 2026-09-30
more than 56% of Pharma & Biotech
The situation: each line is one rule over one dataset
2 trial completion dates slipped in the last 90 days.
What changed in the last 30 days
Nothing new filed in the last 30 days
Watch BMRN
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+1.5%12M
Insider sellForm 144 (planned sale)
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns BMRN: institutional holders (13F)
13F holdings, latest reported quarter
20,445,212 sh
$1.2B
14,844,930 sh
$849.4M
14,190,183 sh
$812.0M
8,743,633 sh
$500.3M
8,648,678 sh
$494.9M
Congress trades in BMRN
No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
BMRN planned insider sales (Form 144)
Notice of intent to sell, filed before any sale
Davis George Eric
Filed 2026-09-02
$1.2M
BMRN mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
Global X Genomics & Biotechnology ETF
$2.3M position · as of 2026-05-31
4.1%
Camelot Event Driven Fund
$4.2M position · as of 2026-06-30
3.6%
First Trust NYSE Arca Biotechnology Index Fund
$79.6M position · as of 2026-06-30
2.8%
Invesco Biotechnology & Genome ETF
$8.0M position · as of 2026-07-31
2.8%
TCW Relative Value Mid Cap Fund
$4.4M position · as of 2026-07-31
2.7%
Miller Intermediate Bond Fund
$3.4M position · as of 2026-07-31
2.1%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Clinical pipeline
43 registered trials, 26 still running (ClinicalTrials.gov).
A status change is dated here weeks before the press release.
3
Phase 1
1 active
9
Phase 2
7 active
8
Phase 3
5 active
3
Phase 4
1 active
13
Not applicable
8 active
7
Multi-phase
4 active
What changed recently
Rapid Drug Desensitization Study in Adults Experiencing Hypersensitivity Reactions to Pa
2026-10-01 · Completion moved 2026-08 → 2026-08-17
Phase 4
Rapid Drug Desensitization Study in Adults Experiencing Hypersensitivity Reactions to Pa
2026-10-01 · Active Not Recruiting → Completed
Phase 4
A Study of Vosoritide in Children With Noonan Syndrome With Inadequate Growth During or
2026-09-24 · Recruiting → Active Not Recruiting
Phase 2
Long-Term Extension Study of Vosoritide to Treat Children With Hypochondroplasia
2026-09-10 · Completion moved 2040-12 → 2044-10
Phase 3
Matched by sponsor name. Trials run under a subsidiary's
own name are not included.
Executive pay vs shareholder return · Jean-Jacques Bienaimé
CEO pay, headline and as actually paid, against the company's
return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2025
$21.9M
$12.2M
$6.4M
-32%
+25%
2024
$14.9M
$2.4M
$6.6M
-25%
-7%
2022
$18.4M
$34.4M
$6.1M
+18%
-10%
2021
$18.3M
$18.4M
$5.5M
+1%
+0%
2020
$18.1M
$22.3M
$5.2M
+4%
+26%
Tagged by the company under SEC Item 402(v). Returns are
cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders have filed to sell, before selling.
The record shows a net $1.3M sold by insiders over 180 days, 292 funds added last quarter, $1.2M in planned Form 144 sales. Each figure is a federal filing, dated the day it went public.
BMRN financials
Revenue growth
+12.9%
XBRL, annual
Net margin
10.8%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$3.4B
four quarters, 2025-07-01 to 2026-06-30
Revenue, TTM BMRN
| FY Dec 2025 | $3.2B |
| FY Dec 2024 | $2.9B |
| FY Dec 2023 | $2.4B |
| FY Dec 2022 | $2.1B |
| FY Dec 2021 | $1.8B |
| Jun 2026 | $989.7M |
| Mar 2026 | $766.2M |
| Dec 2025 | $874.6M |
| Sep 2025 | $776.1M |
| Jun 2025 | $825.4M |
| Mar 2025 | $745.1M |
| Dec 2024 | $747.3M |
| Sep 2024 | $745.7M |
At each fiscal year end
Single quarter
Net margin, TTM
+2.1%
net income over revenue, 2025-07-01 to 2026-06-30
Net margin, TTM BMRN
| FY Dec 2025 | +10.8% |
| FY Dec 2024 | +15.0% |
| FY Dec 2023 | +6.9% |
| FY Dec 2022 | +6.8% |
| FY Dec 2021 | -3.5% |
| Jun 2026 | +4.5% |
| Mar 2026 | +13.8% |
| Dec 2025 | -5.3% |
| Sep 2025 | -4.0% |
| Jun 2025 | +29.1% |
| Mar 2025 | +24.9% |
| Dec 2024 | +16.7% |
| Sep 2024 | +14.2% |
At each fiscal year end
Single quarter
Free cash flow, TTM
$738.2M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Free cash flow, TTM BMRN
| FY Dec 2025 | $725.0M |
| FY Dec 2024 | $487.4M |
| FY Dec 2023 | $62.6M |
| FY Dec 2022 | $54.9M |
| FY Dec 2021 | $209.0M |
| Jun 2026 | $139.3M |
| Mar 2026 | $199.7M |
| Dec 2025 | $58.9M |
| Sep 2025 | $340.2M |
| Jun 2025 | $168.2M |
| Mar 2025 | $157.6M |
| Dec 2024 | $166.1M |
| Sep 2024 | $203.0M |
At each fiscal year end
Single quarter
Debt to equity
0.66x
long-term 2026-06-30 plus current 2026-06-30; equity 2026-06-30
Debt to equity BMRN
| FY Dec 2025 | 0.10x |
| FY Dec 2024 | 0.11x |
| FY Dec 2023 | 0.12x |
| FY Dec 2022 | 0.24x |
| FY Dec 2021 | 0.25x |
| Jun 2026 | 0.66x |
| Mar 2026 | 0.23x |
| Dec 2025 | 0.10x |
| Sep 2025 | 0.10x |
| Jun 2025 | 0.10x |
| Mar 2025 | 0.10x |
| Dec 2024 | 0.11x |
| Sep 2024 | 0.11x |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
0.20x
TTM operating cash flow over long-term 2026-06-30 plus current 2026-06-30
Cash flow to debt BMRN
| FY Dec 2025 | 1.39x |
| FY Dec 2024 | 0.96x |
| FY Dec 2023 | 0.27x |
| FY Dec 2022 | 0.16x |
| FY Dec 2021 | 0.28x |
| Jun 2026 | 0.20x |
| Mar 2026 | 0.61x |
| Dec 2025 | 1.39x |
| Sep 2025 | 1.53x |
| Jun 2025 | 1.29x |
| Mar 2025 | 1.18x |
| Dec 2024 | 0.96x |
| Sep 2024 | 0.70x |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
+1.2%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on equity BMRN
| FY Dec 2025 | +5.9% |
| FY Dec 2024 | +8.0% |
| FY Dec 2023 | +3.5% |
| FY Dec 2022 | +3.2% |
| FY Dec 2021 | -1.5% |
| Jun 2026 | +1.2% |
| Mar 2026 | +4.5% |
| Dec 2025 | +5.9% |
| Sep 2025 | +9.1% |
| Jun 2025 | +11.6% |
| Mar 2025 | +9.6% |
| Dec 2024 | +8.0% |
| Sep 2024 | +6.3% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
+0.8%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets BMRN
| FY Dec 2025 | +4.8% |
| FY Dec 2024 | +6.2% |
| FY Dec 2023 | +2.5% |
| FY Dec 2022 | +2.3% |
| FY Dec 2021 | -1.1% |
| Jun 2026 | +0.8% |
| Mar 2026 | +3.4% |
| Dec 2025 | +4.8% |
| Sep 2025 | +7.2% |
| Jun 2025 | +9.1% |
| Mar 2025 | +7.5% |
| Dec 2024 | +6.2% |
| Sep 2024 | +4.7% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
n/a
effective tax rate 51%, not meaningful
Return on invested capital BMRN
| FY Dec 2025 | +5.5% |
| FY Dec 2024 | +7.6% |
| FY Dec 2023 | +3.6% |
| FY Dec 2022 | +3.1% |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | +3.8% |
| Dec 2025 | +5.5% |
| Sep 2025 | +8.8% |
| Jun 2025 | +11.8% |
| Mar 2025 | +9.4% |
| Dec 2024 | +7.6% |
| Sep 2024 | +5.7% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
+1.8%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
Return on capital employed BMRN
| FY Dec 2025 | +6.2% |
| FY Dec 2024 | +8.0% |
| FY Dec 2023 | +3.2% |
| FY Dec 2022 | +2.9% |
| FY Dec 2021 | -1.5% |
| Jun 2026 | +1.8% |
| Mar 2026 | +4.4% |
| Dec 2025 | +6.2% |
| Sep 2025 | +9.5% |
| Jun 2025 | +12.2% |
| Mar 2025 | +10.1% |
| Dec 2024 | +8.0% |
| Sep 2024 | +6.0% |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
149.59x
close 2026-10-27 over four quarters of diluted EPS, 2025-07-01 to 2026-06-30
P/E, trailing BMRN
| FY Dec 2025 | 33.39x |
| FY Dec 2024 | 29.74x |
| FY Dec 2023 | 110.83x |
| FY Dec 2022 | 139.85x |
| FY Dec 2021 | n/a |
| Jun 2026 | 154.65x |
| Mar 2026 | 41.23x |
| Dec 2025 | 33.39x |
| Sep 2025 | 20.28x |
| Jun 2025 | 16.26x |
| Mar 2025 | 26.18x |
| Dec 2024 | 29.74x |
| Sep 2024 | 42.34x |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
$14.0B
market value at close 2026-10-27 on 2026-07-28 shares, plus long-term 2026-06-30 plus current 2026-06-30, minus cash 2026-06-30
Enterprise value BMRN
| FY Dec 2025 | $10.7B |
| FY Dec 2024 | $12.2B |
| FY Dec 2023 | $18.0B |
| FY Dec 2022 | $19.6B |
| FY Dec 2021 | $16.7B |
| Jun 2026 | $14.4B |
| Mar 2026 | $10.1B |
| Dec 2025 | $10.7B |
| Sep 2025 | $9.7B |
| Jun 2025 | $9.9B |
| Mar 2025 | $13.0B |
| Dec 2024 | $12.2B |
| Sep 2024 | $13.3B |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
+6.9%
TTM free cash flow over market value at close 2026-10-27
FCF yield BMRN
| FY Dec 2025 | +6.3% |
| FY Dec 2024 | +3.9% |
| FY Dec 2023 | +0.3% |
| FY Dec 2022 | +0.3% |
| FY Dec 2021 | +1.3% |
| Jun 2026 | +6.7% |
| Mar 2026 | +7.1% |
| Dec 2025 | +6.3% |
| Sep 2025 | +8.0% |
| Jun 2025 | +6.6% |
| Mar 2025 | +4.6% |
| Dec 2024 | +3.9% |
| Sep 2024 | +2.4% |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
n/a
trailing EPS growth -89%, PEG needs growth
PEG, trailing BMRN
| FY Dec 2025 | n/a |
| FY Dec 2024 | 0.19x |
| FY Dec 2023 | 6.31x |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | 0.33x |
| Jun 2025 | 0.10x |
| Mar 2025 | 0.17x |
| Dec 2024 | 0.19x |
| Sep 2024 | 0.37x |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-27. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-12 | 2024-12 | 2023-12 | 2022-12 | |
|---|---|---|---|---|
| Revenue | $3.2B | $2.9B | $2.4B | $2.1B |
| Operating income | $409.5M | $484.2M | $185.8M | $161.0M |
| Net income | $348.9M | $426.9M | $167.6M | $141.6M |
| EPS (diluted) | 1.80 | 2.21 | 0.87 | 0.75 |
| Operating cash flow | $828.0M | $572.8M | $159.3M | $175.9M |
| Cash | $1.3B | $942.8M | $755.1M | $724.5M |
| Long-term debt | $597.2M | $595.1M | $593.1M | $1.1B |
| Buybacks | n/a | n/a | n/a | $0 |
SEC XBRL, fiscal years, as known on 2026-10-28
BMRN Stock Sonar score 6/7 axes
Find similar shapesCompareBMRN ranks highest on institutional and government (90th percentile) and profitability (83rd), and lowest on insider conviction (16th), among Pharma & Biotech peers.
6 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
BMRN filings, in plain words
Are Biomarin Pharmaceutical insiders buying or selling BMRN?
In the 180 days to 2026-10-28, Biomarin Pharmaceutical insiders were net sellers, a net $1.3M across purchases and sales reported on Form 4, by 2 sellers.
Are there planned insider sales of BMRN?
Yes. 1 Form 144 notice of planned insider sales was filed in the 90 days to 2026-10-28, covering $1.2M of stock; the latest, by Davis George Eric, was filed 2026-09-02.
Read the full summary
In the 180 days to 2026-10-28, Biomarin Pharmaceutical insiders were net sellers of BMRN, a net $1.3M across purchases and sales reported on Form 4 by 2 sellers. Insiders filed 1 Form 144 notice of intent to sell in the 90 days to 2026-10-28, covering $1.2M of stock. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
